Ferring Pharmaceuticals moves forward with early stage development of bacteriophage therapy for inflammatory bowel disease
-Ferring Pharmaceuticals announced today that it will collaborate with Baltimore-based Intralytix, Inc…
Inflammatory Bowel Disease Treatment Gets Boost From New Educational Resource
-A new educational resource for doctors and healthcare professionals will help improve knowledge and treatment of Inflammatory Bowel Disease (IBD)…
Ferring and the Institut Pasteur collaborate in novel IBD drug development project
-Ferring Pharmaceuticals a research-driven, specialty biopharmaceutical group and the Institut Pasteur, a non-profit international biomedical…
Ferring announces European approval of new room temperature stable formulation of PABAL® (carbetocin)
-Ferring announced today that its new room-temperature-stable* formulation of PABAL® (carbetocin) for intravenous (IV) administration…
Ferring Pharmaceuticals acquires novel drug delivery technology from CTCBIO Inc.
-Ferring Pharmaceuticals announced today that it has signed an agreement with CTCBIO Inc. of Seoul, South Korea to acquire rights to…
Archives Press release 2015
Archives Press release 2015